BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Yupelri (Revefenacin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Yupelri (Revefenacin)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07133880-7602@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Yupelri (Revefenacin): Phase 4 readout est. (NCT07133880)
DESCRIPTION:Yupelri (Revefenacin)\, phase 4\, Chronic Obstructive Pulmonary
  Disease.\nStudy: Compare the Effects of Nebulizer Versus Inhaler Based Th
 erapy for COPD Using Long-acting Bronchodilators\nEstimated primary comple
 tion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/revefenacin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07133880
URL:https://assetmemo.bio/drug/revefenacin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07721922-7602@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Yupelri (Revefenacin): Phase 4 readout est. (NCT07721922)
DESCRIPTION:Yupelri (Revefenacin)\, phase 4\, Chronic Obstructive Pulmonary
  Disease.\nStudy: Efficacy of Nebulized Long-Acting Bronchodilators (Formo
 terol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipr
 atropium) in Patients Presenting to the Emergency Department With Acute Ex
 acerbation of COPD (ECOPD)\nEstimated primary completion: 1 September 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/revefenacin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07721922
URL:https://assetmemo.bio/drug/revefenacin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
